• Aethlon Medical filed to execute a 1-for-5 reverse stock split, effective 10 a.m. ET July 31, 2026.
• Split-adjusted trading is expected to start Aug. 4, 2026 on Nasdaq under AEMD; new CUSIP 00808Y703.
• Authorized common shares drop to 20,000,000 from 100,000,000; outstanding shares expected to fall to about 649,914 from 3,249,569.
• Reverse split framed as part of a capital-markets plan, including dilution management and Nasdaq minimum bid-price compliance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005850), on July 31, 2026, and is solely responsible for the information contained therein.